These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 1775605)

  • 21. Double-blind placebo-controlled study with citicoline in APOE genotyped Alzheimer's disease patients. Effects on cognitive performance, brain bioelectrical activity and cerebral perfusion.
    Alvarez XA; Mouzo R; Pichel V; Pérez P; Laredo M; Fernández-Novoa L; Corzo L; Zas R; Alcaraz M; Secades JJ; Lozano R; Cacabelos R
    Methods Find Exp Clin Pharmacol; 1999 Nov; 21(9):633-44. PubMed ID: 10669911
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Double-blind, randomized, placebo-controlled pilot study with anapsos in senile dementia: effects on cognition, brain bioelectrical activity and cerebral hemodynamics.
    Alvarez XA; Pichel V; Pérez P; Laredo M; Corzo D; Zas R; Fernández-Novoa L; Sempere JM; Díaz J; Cacabelos R
    Methods Find Exp Clin Pharmacol; 2000 Sep; 22(7):585-94. PubMed ID: 11196347
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect of growth hormone substitution on cognitive performance in adult patients with hypopituitarism.
    Oertel H; Schneider HJ; Stalla GK; Holsboer F; Zihl J
    Psychoneuroendocrinology; 2004 Aug; 29(7):839-50. PubMed ID: 15177699
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Muscarinic receptor 1 agonist activity of novel N-aryl carboxamide substituted 3-morpholino arecoline derivatives in Alzheimer's presenile dementia models.
    Malviya M; Kumar YC; Mythri RB; Venkateshappa C; Subhash MN; Rangappa KS
    Bioorg Med Chem; 2009 Aug; 17(15):5526-34. PubMed ID: 19595599
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of donepezil over 3 years: an open-label, multicentre study in patients with Alzheimer's disease.
    Burns A; Gauthier S; Perdomo C
    Int J Geriatr Psychiatry; 2007 Aug; 22(8):806-12. PubMed ID: 17199235
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risperidone for psychosis of Alzheimer's disease and mixed dementia: results of a double-blind, placebo-controlled trial.
    Brodaty H; Ames D; Snowdon J; Woodward M; Kirwan J; Clarnette R; Lee E; Greenspan A
    Int J Geriatr Psychiatry; 2005 Dec; 20(12):1153-7. PubMed ID: 16315159
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relationship between pharmacodynamic activity and cognitive effects of eptastigmine in patients with Alzheimer's disease. Eptastigmine Study Group.
    Canal N; Imbimbo BP
    Clin Pharmacol Ther; 1996 Aug; 60(2):218-28. PubMed ID: 8823240
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Physostigmine and arecoline: effects of intravenous infusions in Alzheimer presenile dementia.
    Christie JE; Shering A; Ferguson J; Glen AI
    Br J Psychiatry; 1981 Jan; 138():46-50. PubMed ID: 7023592
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthesis and pharmacological evaluation of novel N-alkyl/aryl substituted thiazolidinone arecoline analogues as muscarinic receptor 1 agonist in Alzheimer's dementia models.
    Sadashiva CT; Chandra JN; Kavitha CV; Thimmegowda A; Subhash MN; Rangappa KS
    Eur J Med Chem; 2009 Dec; 44(12):4848-54. PubMed ID: 19717214
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Measurement of cholinergic drug effects on memory in Alzheimer's disease.
    Brinkman SD; Gershon S
    Neurobiol Aging; 1983; 4(2):139-45. PubMed ID: 6355883
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Memory performance in individuals with primary degenerative dementia: its similarity to diazepam-induced impairments.
    Block RI; DeVoe M; Stanley B; Stanley M; Pomara N
    Exp Aging Res; 1985; 11(3-4):151-5. PubMed ID: 4076305
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Acute effects of the selective cholinergic channel activator (nicotinic agonist) ABT-418 in Alzheimer's disease.
    Potter A; Corwin J; Lang J; Piasecki M; Lenox R; Newhouse PA
    Psychopharmacology (Berl); 1999 Mar; 142(4):334-42. PubMed ID: 10229057
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enhancement of memory processes in Alzheimer's disease with multiple-dose intravenous physostigmine.
    Davis KL; Mohs RC
    Am J Psychiatry; 1982 Nov; 139(11):1421-4. PubMed ID: 6753611
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical trials with the cholinergic drug RS 86 in Alzheimer's disease (AD) and senile dementia of the Alzheimer type (SDAT).
    Wettstein A; Spiegel R
    Psychopharmacology (Berl); 1984; 84(4):572-3. PubMed ID: 6441959
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Longitudinal sensitivity of the Fuld cholinergic profile to Alzheimer's disease.
    Goldman RS; Axelrod BN; Giordani BJ; Foster N; Berent S
    J Clin Exp Neuropsychol; 1992 Jul; 14(4):566-74. PubMed ID: 1400919
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Increased CSF HVA response to arecoline challenge in Alzheimer's disease.
    Pomara N; Stanley M; LeWitt PA; Galloway M; Singh R; Deptula D
    J Neural Transm Gen Sect; 1992; 90(1):53-65. PubMed ID: 1281646
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chronic oral physostigmine without lecithin improves memory in Alzheimer's disease.
    Thal LJ; Masur DM; Blau AD; Fuld PA; Klauber MR
    J Am Geriatr Soc; 1989 Jan; 37(1):42-8. PubMed ID: 2642499
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of oral physostigmine in primary degenerative dementia. A double-blind study of response to different dose level.
    Beller SA; Overall JE; Swann AC
    Psychopharmacology (Berl); 1985; 87(2):147-51. PubMed ID: 3931138
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nicotine patches in Alzheimer's disease: pilot study on learning, memory, and safety.
    Wilson AL; Langley LK; Monley J; Bauer T; Rottunda S; McFalls E; Kovera C; McCarten JR
    Pharmacol Biochem Behav; 1995; 51(2-3):509-14. PubMed ID: 7667377
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Physostigmine effects in Alzheimer's disease: relationship to dementia severity.
    Schwartz AS; Kohlstaedt EV
    Life Sci; 1986 Mar; 38(11):1021-8. PubMed ID: 3512944
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.